

2002

# annual report

O F T H E T R E A T M E N T A C T I O N G R O U P

## 2002 *at a glance*

### JANUARY

HIV vaccine papers in *Nature* by Merck's Emilio Emini, Harvard's Dan Barouch.

### FEBRUARY

First AIDS Treatment Activists Coalition (ATAC) teach-in, Seattle – 70 people attend – followed by ATAC/Bristol-Myers Squibb & Retrovirus conference. National Institutes of Health (NIH) cancels large phase III canarypox HIV vaccine trial.

### MARCH

Radiologist Elias Zerhouni nominated as NIH Director. TAG meetings at Office of AIDS Research (OAR), NIH. TAG co-sponsors 3rd International STI Workshop, Montreal.

### APRIL

Meeting on Roche/Trimeris HIV fusion inhibitor, T-20, Chicago. TAG meets UNAIDS director Peter Piot, is critical of slow-moving UN system. *Indian PWA/activist Ashok Pillai dies of toxoplasmosis, a preventable disease. NYC artist/activist Frank Moore dies of aspergillosis.* Global Fund announces first awards to developing countries to prevent and treat AIDS, tuberculosis & malaria. TAG's Mark Harrington meets with UNAIDS and World Health Organization (WHO) in Geneva.

### MAY

WHO releases first *Guidelines for Antiretroviral Therapy in Resource-Poor Settings*, with input from Mark Harrington. D.C. meeting with World Bank to discuss treatment preparedness. *Activist Linda Grinberg dies in Los Angeles.*

## JUNE

TAG attends 4th World TB Congress in Washington, DC, and convenes steering committee of TAG's planned TB/HIV workshop. After eight years with TAG, Michael Marco leaves TAG for Social & Scientific Systems. Jack Whitescarver becomes OAR Director. Mark attends US AIDS leadership summit in Washington, D.C.

## JULY

Activists disrupt U.S. Health & Human Services Secretary (HHS) Tommy Thompson's speech at Barcelona AIDS conference to protest the Bush administration's underfunding of domestic and global AIDS programs. First meeting of International Treatment Preparedness coalition. *Memorial gathering for Linda Grinberg*. ATAC/Community Constituency Group (CCG) training. TAG receives \$87,750 for TB/HIV workshop.

## AUGUST

Meeting on Roche's Pegasys pegylated interferon for hepatitis C, Nutley, NJ. *Washington Post* covers administration "witch-hunt" against groups involved in July's Thompson demo. Mark attends WHO scale-up meeting in Geneva. Richard Jefferys & Mark attend STI roundtable, Chicago.

## SEPTEMBER

TAG hires Will Berger as administrator. Summit of national/regional AIDS leaders, Washington, D.C. Yet another WHO scale-up meeting in Geneva. Completion of STI Workshop Report 2002 by Richard Jefferys.

## OCTOBER

TAG holds first TB/HIV Coinfection Education & Community Mobilization Workshop in Montreal before 33rd International Union Against Tuberculosis & Lung Diseases (IUATLD) conference. Eighteen activists from developing countries, attend. TAG meets USAID on treatment preparedness. AIDS leaders, including Mark Harrington, meet with Thompson at HHS and with White House AIDS staff.

## NOVEMBER

Roche/Trimeris Fuzeon/T-20 meeting, NYC. HIV superinfection paper by Marcus Altfeld & Bruce Walker appears in *Nature*.

## DECEMBER

6th TAG Research in Action Awards (RIAA) honor community activist Gene Falk, *Newsday* journalist Laurie Garrett, Cornell virologist John Moore and TAG founding director Peter Staley.

**TREATMENT ACTION GROUP, INC.  
STATEMENTS OF FINANCIAL POSITION**

**A S S E T S**

Current assets:	<b>Years ended December 31,</b>	
	<b>2 0 0 2</b>	<b>2 0 0 1</b>
Cash and cash equivalents	\$ 329,254	\$ 222,869
Investment-donated marketable securities, at market	4,687	4,889
Prepaid expenses	820	13,524
Unconditional promises to give – Unrestricted	<u>52,074</u>	<u>47,240</u>
Total current assets	386,835	288,522
 Property and equipment–net of accumulated depreciation	 16,405	 19,430
 Security deposits	 <u>2,756</u>	 <u>2,650</u>
Total assets	<u>\$ 405,996</u>	<u>\$ 310,602</u>

**LIABILITIES AND NET ASSETS**

Current liabilities:		
Accounts payable and accrued expenses	\$ 17,343	\$ 11,239
Total liabilities	<u>17,343</u>	<u>11,239</u>
Net assets:		
Unrestricted	388,653	208,760
Restricted	<u>–</u>	<u>90,603</u>
Total net assets	<u>388,653</u>	<u>299,363</u>
Total liabilities and net assets	<u>\$ 405,996</u>	<u>\$ 310,602</u>

**STATEMENTS OF CASH FLOWS**

Cash flows from operating activities:		
Increase in net assets	\$ 89,290	\$ 5,477
Adjustments to reconcile increase in net assets to net cash provided by operating activities:		
Unrealized loss on marketable securities	202	2,124
Realized (gain) loss on sale of marketable securities	(216)	132
Depreciation	5,804	6,205
Donation of marketable securities	(2,816)	(955)
(Increase) Decrease in current assets:		
Prepaid expenses	12,704	(2,902)
Unconditional promises to give	(4,834)	(16,685)
Security deposits	(106)	(400)
(Decrease) Increase in current liabilities:		
Accrued expenses	<u>6,104</u>	<u>(9,788)</u>
Net cash provided by (used in) operating activities	<u>106,132</u>	<u>(16,792)</u>
Cash flows from investing activities:		
Proceeds from sale of marketable securities	3,032	5,505
Purchases of property and equipment	<u>(2,779)</u>	<u>(13,943)</u>
Net cash provided by (used in) investing activities	<u>253</u>	<u>(8,438)</u>
Net increase (decrease) in cash balance	106,385	(25,230)
Cash, beginning of year	<u>222,869</u>	<u>248,099</u>
Cash, end of year	<u>\$ 329,254</u>	<u>\$ 222,869</u>

**TREATMENT ACTION GROUP, INC.  
STATEMENTS OF ACTIVITIES**

	<b>Years Ended December 31,</b>	
	<b>2 0 0 2</b>	<b>2 0 0 1</b>
Changes in unrestricted net assets		
Revenue and support:		
Bequests	\$ 2,816	\$ 955
Direct mail	32,514	47,674
Donations	7,728	40,762
Grants	565,805	447,539
Special event income	93,028	72,097
Travel and other reimbursement	3,457	6,314
Interest and dividend income	<u>3,682</u>	<u>4,368</u>
	709,030	619,709
Net assets released from donor restrictions	<u>90,603</u>	<u>14,640</u>
Total unrestricted revenue and support	799,633	634,349
Expenses		
Program services		
Antivirals Project	69,904	96,176
Federal Affairs/OAR Project	23,911	30,578
Basic Science Project	88,869	20,316
Infections and Oncology Project	52,731	70,250
Community Outreach	53,442	38,808
TAGline/Website	51,744	60,939
International Projects	<u>115,281</u>	<u>113,477</u>
	455,882	430,544
Supporting services expenses		
Management and general	100,288	120,051
Fundraising	<u>63,584</u>	<u>61,381</u>
Total services expenses	<u>619,754</u>	<u>611,976</u>
Other income (expenses)		
Realized gain (loss) on sale of marketable securities	216	(132)
Unrealized (loss) on marketable securities	<u>(202)</u>	<u>(2,124)</u>
Total other income (expenses)	14	(2,256)
Increase in unrestricted net assets	<u>179,893</u>	<u>20,117</u>
Temporarily restricted net assets		
Net assets released from restrictions:	<u>(90,603)</u>	<u>(14,640)</u>
Decrease in temporary restricted net assets	<u>(90,603)</u>	<u>(14,640)</u>
Increase in total net assets	89,290	<u>5,477</u>
Net assets, beginning of year	<u>299,363</u>	<u>293,886</u>
Net assets, end of year	<u>\$388,653</u>	<u>\$299,363</u>



**BOARD OF DIRECTORS**

Barbara Hughes  
*President*

Laura Morrison  
*Secretary/Treasurer*

Lynda Dee, Esq.  
Richard Lynn, PhD  
Alby P. Maccarone, Jr.  
Sally Morrison  
Mark O'Donnell  
Bruce Schackman, PhD  
Greg Thompson

**BOARD OF ADVISORS**

Arthur J. Ammann, MD  
Constance Benson, MD  
Ross Bleckner  
David Caddick  
Barry Diller  
Matthew Epstein  
Judith Feinberg, MD  
Harvey V. Fineberg, MD, PhD  
Margaret A. Hamburg, MD  
David D. Ho, MD  
Donald Kotler, MD  
Michael Isbell, Esq.  
Mathilde Krim, PhD  
Susan E. Krown, MD  
James G. Pepper  
William G. Powderly, MD  
Joseph A. Sonnabend, MD  
Timothy J. Sweeney  
Tommy Tune  
Urvashi Vaid  
Simon Watney

*In Memoriam*

Jonathan M. Mann, MD, MPH  
Michael Palm  
Elizabeth Glaser

**STAFF**

Mark Harrington  
*Executive Director*

Michael Barr  
*TAGline Editor*

Will Berger  
*Administrator*

Rob Camp  
*Antivirals Project Director*

Richard Jefferys  
*Basic Science Project Director*

Tracy Swan  
*Coinfection Project Director*

**TREATMENT ACTION GROUP**

611 Broadway, Suite 612  
New York, NY 10012  
(212) 253.7922 *phone*  
(212) 253.7923 *fax*

**MISSION STATEMENT**

The Treatment Action Group (TAG) fights to find a cure for AIDS and to ensure that all people living with HIV receive the necessary treatment, care, and information they need to save their lives.

TAG focuses on the AIDS research effort, both public and private, the drug development process, and our nation's and the world's health care delivery systems.

We meet with researchers, pharmaceutical companies, and government officials, and resort when necessary to acts of civil disobedience, or to acts of Congress.

We strive to develop the scientific and political expertise needed to transform policy.

TAG is committed to working for and with all communities affected by HIV.

**ACCOMPLISHMENTS**

Over the past 12 years, TAG has:

- pushed Congress to strengthen AIDS research programs at the National Institutes of Health (NIH).
- helped move twenty new antiretroviral drugs onto the market.
- researched and provided accurate and up-to-date treatment information to hundreds of thousands of people with HIV and their providers, in the U.S. and around the world.
- successfully advocated with key Federal government decision-makers to more than double funding for AIDS research and treatment.

**\$100,000 or more**

Royal S. Marks Foundation

**\$50,000 – \$99,000**

Newman's Own, Inc  
The Office of AIDS Research  
Roche Pharmaceuticals

**\$25,000 – \$49,999**

Bristol-Myers Squibb Virology  
GlaxoSmithKline Inc.  
Merck & Co., Inc.

**\$10,000 – \$24,999**

Agouron Pharmaceuticals, Inc.  
Boehringer-Ingelheim Pharmaceuticals, Inc.  
Bristol-Myers Squibb, Inc.  
Pfizer, Inc.  
JP Morgan Private Bank

**\$5,000 – \$9,999**

Abbott Laboratories  
The Canary Charitable Foundation  
Gilead Sciences, Inc.  
The Gill Foundation  
Robert J. McLain  
The Michael Palm Foundation  
Jerome C. Silvey/Starwood Capital Group Mgt, LLC  
Richard M. Lynn & Joseph Evall  
Mark O'Donnell

**\$2,500 – \$4,999**

Michael A. Becker  
Paul L. Dietz  
Jeffrey B. Soref  
James O. Stepp & Peter Zimmer

**\$1,000 – \$2,499**

Michael Cunningham  
Constance D'Aurizio  
David Dechman  
M. Lee Garrison  
Steven & Judith Gluckstern  
David Hollander  
Lawrence H. Hoskins  
Noel E.D. Kirnon  
Mathilde Krim, Ph.D.  
Cliff Love  
Loring R. McAlpin/The Calamus Foundation  
Mike McCune & Karen Kaye Smith-McCune  
Michel Mercure  
Adam Moss  
Mary C. Rieth  
Jeffrey S. Roth, M.D.  
Bruce Schackman & Ed Sikov  
Evan Schwartz & Robert Fitterman  
William G. Spears  
Nicholas L. Trivisonno  
Tommy Tune  
W. Kirk Wallace & Mark M. Sexton

**\$500 – \$999**

Katherine C. Ash  
Susan Altman Miller  
Benjamin & Christine Anagnos  
John Beach  
William Blumenthal

Robert A. Bronzo  
Donn Campbell  
John Campbell  
Pam Donen  
Sarah Donovan  
Emer Featherstone  
Michael Field  
Linda Greenberg  
James C. Hormel  
Barbara F. Hughes  
Michael D. Paley  
Bette C. Slutsky  
Michael & Melanie Wilson

**\$250 – \$499**

Peter Allen  
David C. Bright, O.D.  
Mark A. Callahan & Lisa Rowland Callahan  
Scott P. Campbell  
Tom Cody  
Robert T. Crane  
Alice Crary & Nathaniel Hupert  
Edward J. Davis & Thomas Phillips  
Edward DeBonis & Vincent Maniscalco  
Peter Diffly  
Carol DiPaolo  
Benjamin F. Doller  
Randall E. Fields  
John S. Fitzgerald  
Stephen K. Friedman

Michael E. Gluck, Ph.D.  
Kenneth L. Goody  
Thaddeus A. Grimes-Gruczka  
Mark Harrington  
Kenneth & Christina Hecht  
Nancy E. Kass  
Paul E. Kennedy  
Horace S. Kenney, III  
Alexandre A. Montagu, Esq.  
Laura A. Morrison  
Ana Oliveira  
Jason I. Osher  
Judith D. Peabody  
William St. Clair Pugh  
Gary Rose  
Susan Rosen  
James & Susan Shehan  
Marvin Shulman  
Betty C. Sikov  
Jane Silver  
Matthew J. Singer  
Grant Stitt & Dr. Alan Shapiro  
Robin S. Weiss & Allan H. Wimer  
Guy T. Westmoreland  
Gary Williams  
David E. Winckoski  
William J. Zwart

THANK YOU.